The Lewis antigens are not integral parts of the red cell membrane but are absorbed onto the cell membrane from plasma (Grubb, 1951; Makela et al., 1967) . The genes of the A, B, 0, Hh, Lewis and secretor (Se) systems are intimately related in the production of the A, B, H, Lea and Leb substances found in body fluids. These substances are glycoproteins or glycolipids composed of approximately 80% carbohydrate and 15% amino acids with an average molecular weight of 300,000 (Kabat, 1956; Watkins, 1966) . The oligosaccharide chains contain predominantly D-galactose (Gal), N-acetylgalactosamine (GalNAc), L-fucose (fuc), and N-acetylglucosamine (GlcNAc). The (Marr et al., 1967; Watkins & Morgan, 1959) .
Interest in the Lewis substances arises from the fact that oncogenic transformation of mucin producing cells often results in the expression and release into circulation of complex carbohydrates whose structures are based on or closely related to the Lewis substances. The recognition of these structures by monoclonal antibodies (mabs) such as 19-9 and CA-50 forms the basis for their use as tumour markers. These mabs were derived by immunising mice with colorectal adenocarcinoma cell lines (Koprowski et al., 1979; Lindholm et al., 1983) . Mab 19-9 was claimed to react specifically with molecules containing a sialylated Lea structure in their nonreducing end (Figure 2 ), lacking in 7-10% of the population with the Lewis phenotype Le (a -b -) (Magnani et al., 1981 (Magnani et al., , 1982 Kabat, 1956; Dienst et al., 1987) . This limits the clinical use of CA 19-9. The simultaneous presence of both N-acetylneuraminic acid (NANA) and fucose was shown to be necessary for the binding of this antibody to the antigen (Magnani et al., 1982) . The mab C-50 was found to react with the same antigenic determinant as 19-9 and an additional antigen in which the fucose residue linked to GlcNAc (Figure 2 ) is absent Mansson et al., 1985) . Hence, the mab C-50 is said to be reactive even in cases where the patients are Le (a -b -) phenotypes.
Both these mabs are available in commercial kits for in vitro diagnostic purposes, and are reported to have good specificity and sensitivity for exocrine pancreatic cancer (Dienst et al., 1987; Heptner et al., 1986; Haglund et al., 1987; Masson et al., 1988) . The main purpose of this study was to (a -b -) ).
The blood groups for each group are shown in Table I . The three-dimensional frequency histogram for tumour antigen concentrations upto 25,000 u ml-' are shown in Figure 4 , showing an almost identical distribution for CA 19-9 and CA-50. Furthermore, the tumour markers were compared to each other using Spearman correlation test. The correlations between CA 19-9 and CA-50 were high both in the case of patients with pancreatic cancer (r = 0.88, P = 0.000, n = 67) and in the total patient material (r = 0.90, P= 0.000, n = 89). Four of the patients with pancreatic cancer had concentrations higher than 25,000 u ml-', two of these were Lewis phenotype Le (a -b + ) and two were Le (a -b -). The highest concentration for CA 19-9 (270,000 u ml-') was found in a patient with Lewis phenotype Le The mean values, medians and standard deviations for CA 19-9 and CA-50 for the three Lewis phenotypes (excluding Le (a + b + )) and non-pancreatic cancer patients are shown in Table II . Although the mean values and the medians for CA-50 and CA 19-9 in patients with pancreatic cancer differ slightly from each other in the group Le (a + b -), more in the group Le (a-b + ) and most in Le (a-b-), these differences are not statistically significant (Mann -Whitney correlation test).
The presence or absence of pancreatic cancer seemed to be of more importance and the differences in the median value either for CA 19-9 or CA-50 concentrations in the pancreatic cancer patients with Lewis phenotype Le (a -b -) differed significantly from the corresponding values for the patients without pancreatic cancer with the same Lewis phenotype (P = 0.005 for CA 19-9 and 0.035 for CA-50 using Mann -Whitney test). This should be assessed against the background that these patients had the same symptoms as the patients with pancreatic cancer (loss of weight, jaundice, etc.) at the time of blood sampling and were investigated due to a strong clinical suspicion of cancer.
Discussion
The Lewis phenotype distribution showed the presence of one patient with Le (a + b + ) in our material. This has been reported before but the normal frequency of the phenotype is very low (in the order of 1:10 000). The normal distribution of the red cell phenotypes Le (a + b -), Le (a -b + ) and Le (a -b -) in a Caucasian population has been reported in textbooks as 20, 73 and 7%, respectively (Kabat, 1956) . The frequency of Le (a -b-) has also been reported to be as high as 10% (Dienst et al., 1987) . Statistical evaluation of the frequency observed by us showed that it differed from 7% but not 10%. We feel that the patient material in our study is limited to permit any definite conclusions regarding these differences to be drawn. The distribution of the A, B, 0 blood groups was as expected and showed no correlation to the values either of CA 19-9 or CA-50. The similarities in the frequency distribution of CA 19-9 and CA-50 in the different Lewis groups, even in the case Le (a -b -), show that the mab 19-9 reacts even in these patients, where one would not expect synthesis of the antigenic determinant. There are some possible reasons for these discrepancies. First, mab 19-9 has a specificity which is broader than that reported. Bearing in mind that the presence of both sialic acid and fucose are necessary for the reactivity, there are two possible structures where the sialic acid can be present, namely on the Lea and the X antigen. Since the reactivity of the mab against structures with type 2 chain (p 1-4 linkage to the penultimate GlcNAc) is approximately 100 times less than analogous structures with type 1 chain (p 1-3 linkage), the sialylated X antigen needs to be produced in much higher concentrations to give appreciable responses (Masson et al., 1989) .
A recent study has shown that the carbohydrate chains having blood group ABH determinants are mainly composed of type 2 chains and that both Lea and X substances are present in human red blood cells as glycolipids irrespective of blood group ABH status (Kannagi et al., 1985) . Heterogeneity in the co-expression of Lea and X (LeX) together with the other antigens Leb and Y (Ley) has been shown in patients with pancreatic cancer, although it was surprising that individuals with Lewis phenotype Le (a -b -) did not react with CA 19-9 mab (Kannagi et al., 1985; Pour et al., 1988) .
Another possibility is that individuals whose red cell phenotype is Le (a -b -) may still be able to produce Lea substances in the tumours as a result of oncogenic transformation. This activates a 1,4 fucosyl transferase responsible for the addition of fucose on a type 1 carbohydrate chain. Such transformations have been speculated since individuals with pancreatic cancer and blood cell phenotype Le (a -b -), were shown to have Lea substance in their serum and saliva (Yazawa et al., 1988) . Although our study showed that the same Lewis phenotypes were obtained in blood and saliva, the possibility of the presence of Lea substances deriving from the tumour cannot be excluded.
The histological distribution of CA 19-9 and CA-50 in pancreatic tissues appear either to be similar, or differs slightly. However, no reaction has been seen for CA 19-9 in patients with Lewis phenotypes Le (a -b -) and the reaction for CA-50 has been weak (Haglund et al., 1986; Schwenk & Makovitzksy, 1989) . This is expected in view of the fact that C-50 mab also recognises sialylated lacto-Ntetraose structure. These results differ from our findings that the reaction of the mab 19-9 does not seem to depend on the Lewis status. It is feasible that the preparation of the tissue for histological studies results in the loss of the glycolipid as well as part of the glycoprotein antigens giving either a weak or no response in some cases.
Finally, in view of the structural complexities and heterogeneity of the carbohydrate structures, it is equally feasible that both the 19-9 and C-50 mabs react with determinants either larger in size or more heterogeneous than the ones described. This has to be further evaluated.
In conclusion, we have found no difference in the plasma expression the hypothesis that oncogenic transformation in most, if not all of these individuals is associated with the activation of a 1,4 fucosyl and other transferases.
